Status:
COMPLETED
Observational Study on the Effect of NovoMix® 30, Levemir® or NovoRapid® (Alone or Combined) in Type 2 Diabetics Previously Treated With Anti-diabetic Medication
Lead Sponsor:
Novo Nordisk A/S
Conditions:
Diabetes
Diabetes Mellitus, Type 2
Eligibility:
All Genders
Brief Summary
This study is conducted in Africa, Asia, South America and Europe. The aim of this observational study is to document the experience with the study insulins when used in routine clinical practice. Aft...
Eligibility Criteria
Inclusion
- After the physician has taken the decision to use NovoMix®30, Levemir® or NovoRapid® (alone or combined), any subject with type 2 diabetes who is not treated with these insulins or who has started on these insulin within the last 4 weeks before inclusion into this study is eligible for the study.
- The selection of the subjects will be at the discretion of the individual physician.
Exclusion
- Subjects treated with NovoMix® 30, Levemir® or NovoRapid® (alone or in combination) for more than 4 weeks before inclusion into this study.
- Subjects who were previously enrolled in this study.
- Subjects with a hypersensitivity to NovoMix® 30, Levemir® or NovoRapid® or to any of the excipients.
- Women who are pregnant, breast feeding or have the intention of becoming pregnant within the next 6 months.
Key Trial Info
Start Date :
November 1 2008
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
March 1 2011
Estimated Enrollment :
66726 Patients enrolled
Trial Details
Trial ID
NCT00869908
Start Date
November 1 2008
End Date
March 1 2011
Last Update
January 19 2017
Active Locations (22)
Enter a location and click search to find clinical trials sorted by distance.
1
Novo Nordisk Investigational Site
Algiers, Algeria, 16035
2
Novo Nordisk Investigational Site
Prov. de Buenos Aires, Argentina, B1636DSU
3
Novo Nordisk Investigational Site
Dhaka, Bangladesh, 1206
4
Novo Nordisk Investigational Site
Beijing, Beijing Municipality, China, 100004